Core Points - The company has completed the change registration of its "Drug Production License" and obtained the new license from the Hunan Provincial Drug Administration [1][2] - The changes include the addition of new production ranges for tablets and raw materials, as well as the acceptance of commissioned production for specific products [1][3] - The new license will not significantly impact the company's existing production structure or current performance [3] Summary of Changes - The production address at 789 Lushong Road, Changsha, Hunan, has added a new production range for tablets, which will only be used for registration purposes [1] - The raw material production facility at 368 Huanglong Road, Tongguan Town, has added new raw materials for registration, including Remdesivir and others [1] - The company will produce Huangtengsu dispersible tablets and Jingangteng dispersible tablets under commission from Hunan Xiangya Pharmaceutical Co., Ltd. [1] - The company will also produce Yinhuang granules under commission from Hunan Ruixin Pharmaceutical Co., Ltd. [1] Impact on the Company - The changes in the "Drug Production License" will not affect the company's existing production capacity, which will remain stable [3] - The company does not expect any significant impact on its current performance due to the new license [3] Product Inclusion in National Medical Insurance - The company's product, Yinxue Qufeng Zhitong Granules, has been included in the 2025 National Medical Insurance Directory, which is expected to enhance its market promotion and sales potential [5][7] - This product is based on a traditional Chinese medicine formula and has not yet been officially launched for sale [6][7] - The company aims to strengthen its position in the market by increasing investment in the research and development of innovative Chinese medicine products [7]

Group 1: Core Views - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its innovative traditional Chinese medicine, Yangxue Qufeng Zhitong Granules, has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales scale [1][3] - The product is based on a modified formula of a well-known traditional Chinese medicine and aims to supplement qi and nourish blood while alleviating pain [1][2] Group 2: Drug Sales Situation - Yangxue Qufeng Zhitong Granules, classified as a Category 1 innovative traditional Chinese medicine, was approved for listing on June 9, 2025, but has not yet officially commenced sales [2] Group 3: Impact on the Company - The inclusion of Yangxue Qufeng Zhitong Granules in the medical insurance directory is anticipated to positively impact the company's future operating performance and market share, although it will not have a significant short-term effect [3] - The company has a strategic goal to become a health industry group centered on innovative traditional Chinese medicine, with plans to increase investment in research and market cultivation [3]

证券代码：603998 证券简称：方盛制药 公告编号：2025-095 湖南方盛制药股份有限公司 关于中药创新药养血祛风止痛颗粒纳入国家医保 目录（2025年）的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据国家医疗保障局网站于2025年12月7日发布的《关于印 发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商 业健康保险创新药品目录>(2025年)的通知》【医保发〔2025〕 33号】，湖南方盛制药股份有限公司（以下简称"公司"）全资 子公司广东方盛健盟药业有限公司独家产品养血祛风止痛颗粒 通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药 品目录》（以下简称"《2025版医保目录》"），公司及控股子 公司其他主要产品本次无退出及增加至《2025版医保目录》的情 况，现将具体情况公告如下： 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 除本次通过医保谈判新纳入《2025版医保目录》的养血祛风 止痛颗粒外，还有公司自主研发的其他中药创新药小 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-096 湖南方盛制药股份有限公司 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、《药品生产许可证》的变更内容 1、在生产地址湖南省长沙市麓松路789号，综合固体二车间 新增丸剂生产范围（仅用于注册申报），所在车间生产线为综合 固体二车间丸剂生产线1，上述剂型及车间生产线通过药品GMP 符合性检查后方可生产上市； 2、在生产地址湖南望城经济开发区铜官镇循环经济工业基 地内黄龙路368号的原料药车间（101车间）新增"原料药（雷美 替胺、非奈利酮、达普司他）（仅用于注册申报）"，车间生产 线为原料药车间（101车间）雷美替胺生产线、非奈利酮生产线、 达普司他生产线，上述品种转A并通过药品GMP符合性检查后方 可生产上市； 第 1页，共 3页 3、接受湖南湘雅制药有限公司委托生产黄藤素分散片（国 药准字Z20150032）、金刚 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its proprietary product, Yao Xue Qu Feng Zhi Tong Granules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to positively impact the product's market promotion and sales scale [1] Group 1 - The product Yao Xue Qu Feng Zhi Tong Granules is an innovative traditional Chinese medicine developed by the company [1] - This is the first time the product has been included in the 2025 Medical Insurance Catalog, which will facilitate its market access and hospital entry [1] - The inclusion is anticipated to have a positive effect on the company's future operating performance and market share, although it will not significantly impact short-term financial results [1]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its exclusive product, Yao Xue Qu Feng Zhi Tong Granules, in the 2025 Medical Insurance Directory, which is expected to positively impact the company's future performance and market share, although the short-term effects will be limited [1] Summary by Categories Product Information - Yao Xue Qu Feng Zhi Tong Granules is classified as a Category 1.1 innovative traditional Chinese medicine and was approved for market launch on June 9, 2025 [1] - The payment standard for the product is set at 7 yuan per bag (8g), with an effective period until December 31, 2027 [1] Market Impact - The inclusion in the medical insurance directory is anticipated to have a positive effect on the company's future performance and market share [1] - There are no changes in the status of other major products, with no exits or additions reported [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its proprietary product, Yao Xue Qu Feng Zhi Tong Granules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to positively impact the product's market promotion and sales scale [1] Group 1 - The product Yao Xue Qu Feng Zhi Tong Granules is an innovative traditional Chinese medicine developed by the company [1] - The inclusion in the 2025 Medical Insurance Catalog will enhance the product's market access and sales potential [1] - The company anticipates a positive impact on future operating performance and market share, although no significant short-term effects on operating results are expected [1]

Group 1: Flu Season Overview - The flu season in China has entered a high incidence period, with flu-like cases in southern and northern provinces reaching 10.3% and 9.1% of total emergency visits, respectively, both higher than the previous week [1] - The demand for flu prevention and control has surged, prompting pharmaceutical companies to increase inventory and supply across all segments, including vaccines, diagnostics, treatments, and drug distribution [1] Group 2: Prevention Efforts - Hualan Biological Engineering Co., Ltd. has reported a significant increase in public awareness regarding flu vaccination, leading to a rise in demand orders from disease control centers compared to the same period last year [1] - The company has efficiently utilized its cold chain logistics to meet the vaccination needs across the country [1] Group 3: Diagnostic Solutions - Shengxiang Biotechnology Co., Ltd. has developed a rapid nucleic acid testing solution for respiratory infections, covering various pathogens and is suitable for outpatient, emergency, and inpatient settings [1] - The company has seen an increase in shipments of respiratory products since October and is well-prepared to meet the testing demand during the flu season [1] Group 4: Treatment Options - The industry is witnessing a collaborative approach in flu treatment, combining Western and traditional Chinese medicine [2] - Beijing Shuanglu Pharmaceutical Co., Ltd. has reported an increase in orders for its flu medications, including Oseltamivir and immune enhancers [2] - Hunan Fangsheng Pharmaceutical Co., Ltd. has noted a significant improvement in sales of respiratory products in the fourth quarter, although overall sales for the year still require monitoring [2] Group 5: Drug Distribution - From November, the sales of flu medications, particularly Oseltamivir and Mabalaoshuai (Sufuda), have seen significant growth at the pharmacy chain, Lao Bai Xing [3] - The company has initiated supply assurance plans ahead of the respiratory disease peak season, ensuring stable market supply through predictive measures and increased inventory [3] - The overall pharmaceutical industry is responding to the flu season by ramping up production and inventory, which not only meets public medication needs but also drives company performance [3]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

Core Insights - On November 24, 2023, brokerage firms set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively [1] Company Summaries - Fangsheng Pharmaceutical is in the traditional Chinese medicine sector and has the highest target price increase among the listed companies [1] - Juhua Co. operates in the chemical products industry and ranks second in target price increase [1] - Meihua Biological, also in the chemical products sector, ranks third with a significant target price increase [1] Brokerage Recommendations - A total of 23 listed companies received brokerage recommendations on November 24, 2023 [1] - Companies such as Keshun Co., Jinhong Group, and Meihua Biological received recommendations from one brokerage firm each [1]